In a 33-year-old man, reinitiating semaglutide at the target dose after a seven week lapse was followed by recurrent symptomatic nausea and vomiting that needed medical intervention.
In plain wordsIn one man, restarting semaglutide at the full dose after a seven week break was followed by repeated nausea and vomiting that needed medical care.
- Peptide
- Semaglutide
- Outcome
- Not applicableNausea and vomiting after reinitiation at target dose
- Study
n = 1
- Outcome group
- Gastrointestinal adverse events · Gastrointestinal
- Studied dose
- Dose not stated · injectableAs given in this study (human).
Source sentences
Despite the extended treatment gap, the patient was directed to reinitiate semaglutide at the target dose rather than starting dose, which was followed by recurrent, symptomatic nausea and vomiting requiring medical intervention.
1 context sentence(design, population, supporting numbers)
Once-weekly injectable semaglutide was prescribed to an outpatient 33-year-old male for chronic weight management.